Late Thursday, The FDA Granted De Novo Marketing Authorization For Renalytix's KidneyIntelX.dkd Prognostic Test, To Assess The Risk Of Progressive Kidney Function Decline In Adults With Diabetes, Early-stage Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted De Novo marketing authorization for Renalytix's KidneyIntelX.dkd prognostic test. The test is designed to assess the risk of progressive kidney function decline in adults with diabetes and early-stage kidney disease.
June 30, 2023 | 8:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Renalytix has received FDA approval for its KidneyIntelX.dkd prognostic test. This could potentially increase the company's market share and revenue.
FDA approval is a significant milestone for any healthcare company. It not only validates the product's safety and efficacy but also opens up the market for the product. This could potentially lead to increased sales and revenue for Renalytix, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100